AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
suxamethonium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| quaternary ammonium compounds | 2489 | 306-40-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 59 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,EPHB4,FLT3,GRK2,MAP3K9,MAPK7,SIK2,STK33,TEK,TTK | 16 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 20, 1952 | FDA | SANDOZ |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 693.41 | 41.97 | 191 | 5295 | 31426 | 90591535 |
| Cardiac arrest | 255.09 | 41.97 | 125 | 5361 | 104810 | 90518151 |
| Hyperthermia malignant | 253.79 | 41.97 | 47 | 5439 | 1251 | 90621710 |
| Hypotension | 251.60 | 41.97 | 185 | 5301 | 325212 | 90297749 |
| Anaphylactic reaction | 188.17 | 41.97 | 96 | 5390 | 87428 | 90535533 |
| Exposure during pregnancy | 180.36 | 41.97 | 134 | 5352 | 238276 | 90384685 |
| Maternal exposure during delivery | 176.59 | 41.97 | 42 | 5444 | 3804 | 90619157 |
| Diabetes insipidus | 162.79 | 41.97 | 38 | 5448 | 3174 | 90619787 |
| Maternal exposure during pregnancy | 134.16 | 41.97 | 135 | 5351 | 359928 | 90263033 |
| Bronchospasm | 132.09 | 41.97 | 49 | 5437 | 20660 | 90602301 |
| Neuromuscular block prolonged | 129.94 | 41.97 | 24 | 5462 | 628 | 90622333 |
| Renal ischaemia | 129.43 | 41.97 | 24 | 5462 | 642 | 90622319 |
| Tracheal deviation | 128.92 | 41.97 | 21 | 5465 | 255 | 90622706 |
| Apnoea | 126.52 | 41.97 | 39 | 5447 | 9375 | 90613586 |
| PCO2 increased | 124.69 | 41.97 | 26 | 5460 | 1287 | 90621674 |
| Phrenic nerve paralysis | 123.94 | 41.97 | 21 | 5465 | 329 | 90622632 |
| Status epilepticus | 110.68 | 41.97 | 42 | 5444 | 18832 | 90604129 |
| Ventricular tachycardia | 103.08 | 41.97 | 43 | 5443 | 24665 | 90598296 |
| Blood pH decreased | 102.32 | 41.97 | 25 | 5461 | 2533 | 90620428 |
| PO2 increased | 98.38 | 41.97 | 20 | 5466 | 872 | 90622089 |
| Delayed recovery from anaesthesia | 95.51 | 41.97 | 20 | 5466 | 1010 | 90621951 |
| Rhabdomyolysis | 95.09 | 41.97 | 51 | 5435 | 51205 | 90571756 |
| Oxygen saturation abnormal | 94.10 | 41.97 | 26 | 5460 | 4262 | 90618699 |
| Blood bicarbonate decreased | 92.52 | 41.97 | 24 | 5462 | 3095 | 90619866 |
| Bradycardia | 91.08 | 41.97 | 59 | 5427 | 83788 | 90539173 |
| Seizure | 87.50 | 41.97 | 73 | 5413 | 152556 | 90470405 |
| Left ventricular dysfunction | 87.29 | 41.97 | 33 | 5453 | 14636 | 90608325 |
| Drug interaction | 87.26 | 41.97 | 95 | 5391 | 276358 | 90346603 |
| Foetal death | 86.21 | 41.97 | 36 | 5450 | 20687 | 90602274 |
| Foetal exposure during pregnancy | 83.20 | 41.97 | 44 | 5442 | 42931 | 90580030 |
| Pseudocholinesterase deficiency | 78.77 | 41.97 | 12 | 5474 | 91 | 90622870 |
| Premature delivery | 75.92 | 41.97 | 40 | 5446 | 38722 | 90584239 |
| Premature baby | 73.32 | 41.97 | 34 | 5452 | 25043 | 90597918 |
| Anaesthetic complication neurological | 66.47 | 41.97 | 14 | 5472 | 727 | 90622234 |
| Serotonin syndrome | 65.52 | 41.97 | 36 | 5450 | 37851 | 90585110 |
| Hyperkalaemia | 63.93 | 41.97 | 43 | 5443 | 64921 | 90558040 |
| Electroencephalogram abnormal | 63.72 | 41.97 | 19 | 5467 | 4077 | 90618884 |
| Unwanted awareness during anaesthesia | 62.21 | 41.97 | 12 | 5474 | 398 | 90622563 |
| Renal impairment | 59.49 | 41.97 | 50 | 5436 | 105371 | 90517590 |
| Anaesthetic complication | 58.97 | 41.97 | 16 | 5470 | 2449 | 90620512 |
| Paralysis | 58.23 | 41.97 | 23 | 5463 | 11455 | 90611506 |
| Schizencephaly | 58.03 | 41.97 | 11 | 5475 | 332 | 90622629 |
| Cerebral haemorrhage foetal | 57.87 | 41.97 | 11 | 5475 | 337 | 90622624 |
| Blood magnesium decreased | 54.50 | 41.97 | 24 | 5462 | 15669 | 90607292 |
| Patent ductus arteriosus | 53.32 | 41.97 | 17 | 5469 | 4552 | 90618409 |
| Premature labour | 51.50 | 41.97 | 22 | 5464 | 13354 | 90609607 |
| Normal newborn | 51.17 | 41.97 | 26 | 5460 | 23336 | 90599625 |
| Phaeochromocytoma crisis | 50.97 | 41.97 | 10 | 5476 | 363 | 90622598 |
| Hypoxia | 50.74 | 41.97 | 39 | 5447 | 72360 | 90550601 |
| Circulatory collapse | 49.60 | 41.97 | 26 | 5460 | 24878 | 90598083 |
| Clonus | 49.48 | 41.97 | 17 | 5469 | 5733 | 90617228 |
| Ventricular fibrillation | 47.23 | 41.97 | 21 | 5465 | 14023 | 90608938 |
| Encephalopathy | 46.29 | 41.97 | 31 | 5455 | 46413 | 90576548 |
| Pulseless electrical activity | 45.66 | 41.97 | 18 | 5468 | 8914 | 90614047 |
| Kounis syndrome | 44.79 | 41.97 | 13 | 5473 | 2540 | 90620421 |
| Unresponsive to stimuli | 44.26 | 41.97 | 28 | 5458 | 38093 | 90584868 |
| Diarrhoea | 42.49 | 41.97 | 4 | 5482 | 939186 | 89683775 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperthermia malignant | 487.87 | 31.94 | 98 | 3942 | 2560 | 42614735 |
| Anaphylactic shock | 338.33 | 31.94 | 114 | 3926 | 23403 | 42593892 |
| Cardiac arrest | 193.26 | 31.94 | 123 | 3917 | 109197 | 42508098 |
| Serotonin syndrome | 160.98 | 31.94 | 68 | 3972 | 25777 | 42591518 |
| Anaphylactic reaction | 148.56 | 31.94 | 75 | 3965 | 42668 | 42574627 |
| Rhabdomyolysis | 116.16 | 31.94 | 79 | 3961 | 77940 | 42539355 |
| Neuromuscular block prolonged | 114.46 | 31.94 | 23 | 4017 | 596 | 42616699 |
| Pseudocholinesterase deficiency | 97.63 | 31.94 | 15 | 4025 | 72 | 42617223 |
| Hypotension | 91.81 | 31.94 | 117 | 3923 | 257514 | 42359781 |
| Electrocardiogram ST segment elevation | 85.98 | 31.94 | 29 | 4011 | 5910 | 42611385 |
| Procedural hypotension | 71.30 | 31.94 | 17 | 4023 | 986 | 42616309 |
| Anaesthetic complication | 64.99 | 31.94 | 17 | 4023 | 1440 | 42615855 |
| Respiratory acidosis | 61.52 | 31.94 | 23 | 4017 | 6308 | 42610987 |
| Drug interaction | 60.65 | 31.94 | 98 | 3942 | 266901 | 42350394 |
| Bradycardia | 60.64 | 31.94 | 56 | 3984 | 85428 | 42531867 |
| Bronchospasm | 57.89 | 31.94 | 27 | 4013 | 12858 | 42604437 |
| Seizure like phenomena | 54.76 | 31.94 | 14 | 4026 | 1083 | 42616212 |
| Apnoea | 53.43 | 31.94 | 22 | 4018 | 7781 | 42609514 |
| Ventricular tachycardia | 48.26 | 31.94 | 32 | 4008 | 30128 | 42587167 |
| Metabolic acidosis | 46.84 | 31.94 | 39 | 4001 | 51819 | 42565476 |
| Muscle rigidity | 44.26 | 31.94 | 22 | 4018 | 12037 | 42605258 |
| Therapeutic product effect prolonged | 42.33 | 31.94 | 9 | 4031 | 309 | 42616986 |
| Paralysis | 42.06 | 31.94 | 18 | 4022 | 7002 | 42610293 |
| Pulseless electrical activity | 42.03 | 31.94 | 19 | 4021 | 8418 | 42608877 |
| Hyporesponsive to stimuli | 41.03 | 31.94 | 12 | 4028 | 1534 | 42615761 |
| Tachycardia | 40.74 | 31.94 | 49 | 3991 | 101038 | 42516257 |
| Cardio-respiratory arrest | 40.74 | 31.94 | 38 | 4002 | 58598 | 42558697 |
| Hypoxia | 38.74 | 31.94 | 40 | 4000 | 69746 | 42547549 |
| Pigment nephropathy | 38.21 | 31.94 | 6 | 4034 | 34 | 42617261 |
| Stress cardiomyopathy | 37.94 | 31.94 | 13 | 4027 | 2772 | 42614523 |
| Trismus | 37.50 | 31.94 | 13 | 4027 | 2871 | 42614424 |
| Hyperkalaemia | 37.43 | 31.94 | 42 | 3998 | 80416 | 42536879 |
| Blood creatine phosphokinase increased | 36.84 | 31.94 | 33 | 4007 | 48305 | 42568990 |
| Pseudomonal sepsis | 36.10 | 31.94 | 14 | 4026 | 4235 | 42613060 |
| Neuromuscular blockade | 35.90 | 31.94 | 8 | 4032 | 343 | 42616952 |
| Haemodynamic instability | 34.87 | 31.94 | 19 | 4021 | 12538 | 42604757 |
| Muscle contractions involuntary | 33.69 | 31.94 | 11 | 4029 | 2023 | 42615272 |
| Diarrhoea | 32.85 | 31.94 | 3 | 4037 | 460846 | 42156449 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 1006.50 | 30.99 | 306 | 8976 | 51240 | 110528777 |
| Hyperthermia malignant | 709.56 | 30.99 | 140 | 9142 | 3760 | 110576257 |
| Cardiac arrest | 424.28 | 30.99 | 241 | 9041 | 196512 | 110383505 |
| Anaphylactic reaction | 332.59 | 30.99 | 171 | 9111 | 114129 | 110465888 |
| Hypotension | 312.02 | 30.99 | 294 | 8988 | 523555 | 110056462 |
| Neuromuscular block prolonged | 240.26 | 30.99 | 47 | 9235 | 1200 | 110578817 |
| Rhabdomyolysis | 200.22 | 30.99 | 125 | 9157 | 120276 | 110459741 |
| Serotonin syndrome | 187.84 | 30.99 | 94 | 9188 | 59059 | 110520958 |
| Pseudocholinesterase deficiency | 182.08 | 30.99 | 29 | 9253 | 210 | 110579807 |
| Bronchospasm | 181.78 | 30.99 | 75 | 9207 | 30164 | 110549853 |
| Maternal exposure during delivery | 161.12 | 30.99 | 41 | 9241 | 3524 | 110576493 |
| Bradycardia | 148.85 | 30.99 | 115 | 9167 | 155402 | 110424615 |
| Ventricular tachycardia | 145.70 | 30.99 | 75 | 9207 | 49934 | 110530083 |
| Exposure during pregnancy | 143.47 | 30.99 | 116 | 9166 | 167308 | 110412709 |
| Apnoea | 140.12 | 30.99 | 50 | 9232 | 13589 | 110566428 |
| Drug interaction | 130.98 | 30.99 | 184 | 9098 | 499999 | 110080018 |
| Diabetes insipidus | 123.47 | 30.99 | 38 | 9244 | 6532 | 110573485 |
| Delayed recovery from anaesthesia | 122.75 | 30.99 | 30 | 9252 | 2185 | 110577832 |
| Anaesthetic complication | 122.19 | 30.99 | 33 | 9249 | 3573 | 110576444 |
| Maternal exposure during pregnancy | 121.20 | 30.99 | 127 | 9155 | 254756 | 110325261 |
| PCO2 increased | 120.95 | 30.99 | 29 | 9253 | 1948 | 110578069 |
| Tracheal deviation | 120.44 | 30.99 | 21 | 9261 | 277 | 110579740 |
| Phrenic nerve paralysis | 106.23 | 30.99 | 21 | 9261 | 566 | 110579451 |
| Renal ischaemia | 96.57 | 30.99 | 25 | 9257 | 2298 | 110577719 |
| Respiratory acidosis | 95.81 | 30.99 | 38 | 9244 | 13788 | 110566229 |
| Blood pH decreased | 91.97 | 30.99 | 28 | 9254 | 4641 | 110575376 |
| Paralysis | 91.37 | 30.99 | 38 | 9244 | 15562 | 110564455 |
| Electrocardiogram ST segment elevation | 88.14 | 30.99 | 32 | 9250 | 9128 | 110570889 |
| Status epilepticus | 88.04 | 30.99 | 46 | 9236 | 31525 | 110548492 |
| PO2 increased | 85.80 | 30.99 | 21 | 9261 | 1538 | 110578479 |
| Hypoxia | 84.85 | 30.99 | 77 | 9205 | 129438 | 110450579 |
| Foetal death | 83.70 | 30.99 | 36 | 9246 | 16009 | 110564008 |
| Anaesthetic complication neurological | 83.51 | 30.99 | 19 | 9263 | 1014 | 110579003 |
| Oxygen saturation abnormal | 82.83 | 30.99 | 27 | 9255 | 5584 | 110574433 |
| Tachycardia | 80.37 | 30.99 | 97 | 9185 | 226548 | 110353469 |
| Pulseless electrical activity | 78.97 | 30.99 | 35 | 9247 | 16722 | 110563295 |
| Diarrhoea | 76.33 | 30.99 | 5 | 9277 | 1139500 | 109440517 |
| Cardio-respiratory arrest | 74.17 | 30.99 | 68 | 9214 | 115768 | 110464249 |
| Left ventricular dysfunction | 73.52 | 30.99 | 37 | 9245 | 23456 | 110556561 |
| Therapeutic product effect prolonged | 73.38 | 30.99 | 16 | 9266 | 702 | 110579315 |
| Procedural hypotension | 71.34 | 30.99 | 20 | 9262 | 2485 | 110577532 |
| Stress cardiomyopathy | 71.24 | 30.99 | 32 | 9250 | 15774 | 110564243 |
| Seizure | 70.91 | 30.99 | 90 | 9192 | 221095 | 110358922 |
| Blood bicarbonate decreased | 70.08 | 30.99 | 24 | 9258 | 5773 | 110574244 |
| Hyperkalaemia | 68.64 | 30.99 | 70 | 9212 | 135726 | 110444291 |
| Premature delivery | 64.30 | 30.99 | 37 | 9245 | 30595 | 110549422 |
| Neuromuscular blockade | 61.85 | 30.99 | 14 | 9268 | 730 | 110579287 |
| Fatigue | 60.67 | 30.99 | 14 | 9268 | 1215944 | 109364073 |
| Metabolic acidosis | 58.92 | 30.99 | 56 | 9226 | 99688 | 110480329 |
| Electroencephalogram abnormal | 57.28 | 30.99 | 21 | 9261 | 6152 | 110573865 |
| Ventricular fibrillation | 56.51 | 30.99 | 38 | 9244 | 41275 | 110538742 |
| Muscle rigidity | 55.77 | 30.99 | 31 | 9251 | 24000 | 110556017 |
| Haemodynamic instability | 54.41 | 30.99 | 30 | 9252 | 22858 | 110557159 |
| Drug ineffective | 54.33 | 30.99 | 261 | 9021 | 1520279 | 109059738 |
| Premature labour | 52.55 | 30.99 | 22 | 9260 | 9150 | 110570867 |
| Unwanted awareness during anaesthesia | 52.51 | 30.99 | 11 | 9271 | 398 | 110579619 |
| Nausea | 51.18 | 30.99 | 20 | 9262 | 1235670 | 109344347 |
| Circulatory collapse | 50.47 | 30.99 | 36 | 9246 | 42957 | 110537060 |
| Clonus | 50.25 | 30.99 | 21 | 9261 | 8695 | 110571322 |
| Post procedural complication | 50.16 | 30.99 | 30 | 9252 | 26628 | 110553389 |
| Unresponsive to stimuli | 49.94 | 30.99 | 42 | 9240 | 63748 | 110516269 |
| Trismus | 48.75 | 30.99 | 19 | 9263 | 6577 | 110573440 |
| Fear | 48.63 | 30.99 | 28 | 9254 | 23165 | 110556852 |
| Normal newborn | 47.43 | 30.99 | 27 | 9255 | 21869 | 110558148 |
| Allergy test negative | 46.76 | 30.99 | 10 | 9272 | 400 | 110579617 |
| Negative pressure pulmonary oedema | 46.64 | 30.99 | 11 | 9271 | 688 | 110579329 |
| Seizure like phenomena | 45.36 | 30.99 | 14 | 9268 | 2427 | 110577590 |
| Hypercapnia | 45.27 | 30.99 | 21 | 9261 | 11138 | 110568879 |
| Phaeochromocytoma crisis | 44.51 | 30.99 | 10 | 9272 | 504 | 110579513 |
| Blood magnesium decreased | 44.24 | 30.99 | 25 | 9257 | 19971 | 110560046 |
| Anaphylactoid shock | 42.88 | 30.99 | 11 | 9271 | 975 | 110579042 |
| Arthralgia | 40.80 | 30.99 | 8 | 9274 | 779624 | 109800393 |
| Laryngospasm | 40.08 | 30.99 | 15 | 9267 | 4653 | 110575364 |
| Anhedonia | 38.82 | 30.99 | 21 | 9261 | 15407 | 110564610 |
| Headache | 38.64 | 30.99 | 13 | 9269 | 882364 | 109697653 |
| Hypotonia | 38.42 | 30.99 | 21 | 9261 | 15724 | 110564293 |
| Emotional distress | 38.17 | 30.99 | 31 | 9251 | 44816 | 110535201 |
| Muscle contractions involuntary | 37.14 | 30.99 | 14 | 9268 | 4430 | 110575587 |
| Generalised tonic-clonic seizure | 36.73 | 30.99 | 33 | 9249 | 54647 | 110525370 |
| Renal impairment | 35.92 | 30.99 | 60 | 9222 | 188385 | 110391632 |
| Symptom masked | 35.77 | 30.99 | 11 | 9271 | 1884 | 110578133 |
| Pigment nephropathy | 35.01 | 30.99 | 6 | 9276 | 71 | 110579946 |
| Blood creatine phosphokinase increased | 33.89 | 30.99 | 36 | 9246 | 73041 | 110506976 |
| Tryptase increased | 33.69 | 30.99 | 9 | 9273 | 934 | 110579083 |
| Respiratory depression | 33.48 | 30.99 | 25 | 9257 | 31976 | 110548041 |
| Blood calcium decreased | 33.11 | 30.99 | 26 | 9256 | 35819 | 110544198 |
| Bradyarrhythmia | 32.23 | 30.99 | 13 | 9269 | 4921 | 110575096 |
| Myoclonic epilepsy | 31.98 | 30.99 | 11 | 9271 | 2680 | 110577337 |
| Airway complication of anaesthesia | 31.56 | 30.99 | 8 | 9274 | 676 | 110579341 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03AB01 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Choline derivatives |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D009467 | Neuromuscular Depolarizing Agents |
| FDA EPC | N0000175719 | Depolarizing Neuromuscular Blocker |
| FDA PE | N0000175733 | Neuromuscular Depolarizing Blockade |
| CHEBI has role | CHEBI:51371 | muscle relaxant |
| CHEBI has role | CHEBI:51372 | neuromuscular agent |
| CHEBI has role | CHEBI:88188 | drug allergen |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Muscle relaxation, function | indication | 11977004 | |
| General anesthesia | indication | 50697003 | |
| Skeletal Muscle Relaxation for Endotracheal Intubation | indication | ||
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Hypocalcemia | contraindication | 5291005 | |
| Poisoning by digitalis glycoside | contraindication | 12876009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Infectious disease | contraindication | 40733004 | |
| Myxedema | contraindication | 43153006 | DOID:11634 |
| Hypokalemia | contraindication | 43339004 | |
| Burn injury | contraindication | 48333001 | |
| Bradycardia | contraindication | 48867003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Muscular dystrophy | contraindication | 73297009 | DOID:9884 |
| Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
| Third degree burn injury | contraindication | 80247002 | |
| Spinal cord injury | contraindication | 90584004 | |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Fracture of bone | contraindication | 125605004 | |
| Disorder of muscle | contraindication | 129565002 | DOID:423 |
| Spasticity | contraindication | 221360009 | |
| Rhabdomyolysis | contraindication | 240131006 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Injury of eye region | contraindication | 282752000 | |
| Deficiency of cholinesterase | contraindication | 360607009 | |
| At risk for aspiration | contraindication | 371736008 | |
| Primary malignant neoplasm | contraindication | 372087000 | |
| Surgical procedure on eye proper | contraindication | 373353005 | |
| Fever | contraindication | 386661006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Malignant hyperthermia | contraindication | 405501007 | |
| Cardiac arrest | contraindication | 410429000 | DOID:0060319 |
| Traumatic injury | contraindication | 417746004 | |
| Cardiac Decompensation | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscle-type nicotinic acetylcholine receptor | Ion channel | AGONIST | CHEMBL | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 4.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017730 | VUID |
| N0000178917 | NUI |
| D00766 | KEGG_DRUG |
| 71-27-2 | SECONDARY_CAS_RN |
| 4017730 | VANDF |
| 4019935 | VANDF |
| C0038627 | UMLSCUI |
| CHEBI:45652 | CHEBI |
| SCK | PDB_CHEM_ID |
| CHEMBL703 | ChEMBL_ID |
| CHEMBL983 | ChEMBL_ID |
| DB00202 | DRUGBANK_ID |
| 5314 | PUBCHEM_CID |
| 10154 | RXNORM |
| 1940 | MMSL |
| 5517 | MMSL |
| d00376 | MMSL |
| 001676 | NDDF |
| 005590 | NDDF |
| 372724004 | SNOMEDCT_US |
| 3822002 | SNOMEDCT_US |
| 58907007 | SNOMEDCT_US |
| D013390 | MESH_DESCRIPTOR_UI |
| 4004 | IUPHAR_LIGAND_ID |
| 26 | INN_ID |
| J2R869A8YF | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9983 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 16 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9983 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 16 sections |
| QUELICIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6629 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 27 sections |
| QUELICIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6970 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 27 sections |
| Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3411 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 24 sections |
| Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9053 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 24 sections |
| Succinylcholine Chloride | Human Prescription Drug Label | 1 | 14445-407 | INJECTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-981 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-371 | INJECTION | 200 mg | INTRAMUSCULAR | ANDA | 24 sections |
| Succinylcholine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-666 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 24 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1353 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1525 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 12 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1526 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
| Succinylcholine Chloride | Human prescription drug label | 1 | 52817-734 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 22 sections |
| SUCCINYLCHOLINE CHLORIDE | Human Prescription Drug Label | 1 | 55150-315 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 25 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-943 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-232 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 17 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-232 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 17 sections |
| Succinylcholine Chloride | Human Prescription Drug Label | 1 | 68083-450 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 25 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-700 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-700 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-301 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-783 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1581 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 25 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4409 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 24 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1377 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 24 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70756-613 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 23 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1352 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 2 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-719 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 26 sections |
| Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-719 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 26 sections |